Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

3articles mentioning institutions

4institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: Lancet Oncol ×

Lancet Oncol

This institution is selected. Its supporting articles are shown below.

Lancet Oncol3

Articles mentioning Lancet Oncol

3 articles · page 1 of 1

1209 Unequal global survival gains from immune checkpoint inhibitors: a 30-year mortality-to-incidence analysis highlighting access-driven disparities in ICI-responsive cancers

jitc · abstract · 2025-11-04 · 2 matching annotations

90.4%

Lancet Oncol JAMA Oncol melanoma non-small cell lung Stomach cancer Immune Checkpoint Inhibitors World Bank kidney kidney cancer

…fordable cancer care in low-income and middle-income countries. Lancet Oncol. 2014;15(3):e119-e128.Abstract 1209 Figure 1Trends in mortality…

5PSQ-057 Case report: combination therapy with mogamulizumab and DA-EPOCH chemotherapy in refractory sézary syndrome

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

88.1%

Lancet Oncol secondary-level hospital mogamulizumab cutaneous T-cell lymphoma methotrexate doxorubicin aprepitant Sézary syndrome (SS)DA-EPOCH DA-EPOCH chemotherapy

…sus vorinostat in previously treated cutaneous T-cell lymphoma. Lancet Oncol. 2018;19(9):1192–1204.Conflict of Interest No conflict of inter…

530 CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study

jitc · abstract · 2025-11-04 · 1 matching annotations

86.5%

Lancet Oncol Mitazalimab mFOLFIRINOX

…inoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. Lancet Oncol, 2024.Geboes KP, et al. 592 CD40 agonist mitazalimab combined w…